Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sorafenib Long Term Extension Program

Trial Profile

Sorafenib Long Term Extension Program

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2018

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Acronyms STEP
  • Sponsors Bayer
  • Most Recent Events

    • 10 Sep 2018 Planned End Date changed from 28 Jun 2019 to 30 Jun 2020.
    • 10 Sep 2018 Planned primary completion date changed from 28 Jun 2019 to 30 Jun 2020.
    • 12 Jul 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top